Regado Biosciences Inc (RGDO) 1.17 $RGDO
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), PSTI: 2.91 (+0.01), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), EGRX: 20.98 (+1.45), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
CorMedix (CRMD) Looks Good: Stock Moves 9.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:25AM CST
CorMedix (CRMD) was a big mover last session, with shares rising over 9% on the day.
CRMD: 3.27 (+0.02), RGDO: 1.17 (+0.02)
Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 4:25PM CST
Celldex Therapeutics (CLDX) and Bristol-Myers Squibb Company (BMY) announced the commencement of a phase I/II dose escalation and cohort expansion study to evaluate Celldex's varlilumab in combination with Bristol-Myers' Opdivo in patients with advanced refractory solid tumor.
CLDX: 20.97 (+0.53), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:54PM CST
Intercept Pharmaceuticals, Inc.'s (ICPT) obeticholic acid (OCA) received Breakthrough Therapy designation from the FDA for nonalcoholic steatohepatitis (NASH).
MNK: 115.01 (+2.51), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
SurModics Beats on Q1 Earnings, Reaffirms 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 9:20AM CST
SurModics, Inc.'s first-quarter fiscal 2015 (ended Dec 31, 2014) adjusted earnings of 25 cents per share beat the Zacks Consensus Estimate by 4 cents.
SRDX: 23.53 (+0.10), AMAG: 41.49 (+0.23), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:20PM CST
Alexion Pharmaceuticals' (ALXN) fourth-quarter 2014 earnings (including stock-based compensation expense) of $1.15 per share.
ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Salix Financial Results Need Correcting: Audit Committee - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:19PM CST
The audit committee of the board of directors of Salix Pharmaceuticals (SLXP) announced that the company's consolidated financials require corrections.
ALXN: 182.29 (+6.02), SLXP: 152.35 (+3.17), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:07PM CST
BioDelivery (BDSI) entered into an agreement with Meda to obtain marketing authorizations for Onsolis.
BDSI: 14.92 (+0.93), OPHT: 51.11 (+0.12), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Celgene Q4 Earnings & Revenues In Line, Revlimid Sales Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 9:51AM CST
Celgene Corporation (CELG) reported fourth-quarter 2014 earnings of 88 cents per share.
ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
MediciNova (MNOV) in Focus: Stock Moves 9.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 8:25AM CST
MediciNova (MNOV) was a big mover last session, as the company saw its shares rising roughly 10% on the day.
MNOV: 3.62 (-0.56), RGDO: 1.17 (+0.02)
Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 5:25PM CST
Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB (also known as Sanfilippo B syndrome).
BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Illumina Tops Q4 Earnings on Solid Revenues, Margin Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:30AM CST
Illumina's (ILMN) full year 2014 adjusted earnings came in at $2.74 per share, beating the Zacks Consensus Estimate by 3.4% and reflecting an improvement of 52.2% from the year-ago quarter's equivalent figure.
OPHT: 51.11 (+0.12), ILMN: 198.54 (+1.81), PRTA: 22.89 (+0.13), RGDO: 1.17 (+0.02)
Strength Seen in ZIOPHARM (ZIOP): Stock Rises 11.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:25AM CST
ZIOPHARM (ZIOP) was a big mover last session, with its shares rising roughly 12% on the day.
ZIOP: 9.64 (-0.35), RGDO: 1.17 (+0.02)
Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 5:55PM CST
Gilead Sciences, Inc. (GILD) expanded HCV licensing agreements with India-based partners to include an investigational pan-genotypic agent, GS-5816.
GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 5:30PM CST
The Medicines Company (MDCO) announced that the CHMP has issued positive opinions regarding the marketing authorization for Orbactiv, Raplixa and Kengrexal.
MDCO: 29.79 (+0.91), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Atrial Fibrillation Therapeutic Pipeline Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 3:31PM CST
The report "Atrial Fibrillation - Pipeline Review, H2 2015" provides comprehensive information on the therapeutic development for atrial fibrillation. Atrial fibrillation is the most ordinary type of arrhythmia. Atrial fibrillation is an unbalanced heartbeat that increases the threat of stroke and heart disease. Generally, the risk of developing atrial fibrillation increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The complete report is available at http://www.rnrmarketresearch.com/atrial-fibri...eport.html .
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
The 2015 Calendar Of NASH Trial Catalysts: Takeda And Tobira
Clinically Sound Investor - at Seeking Alpha - Fri Jan 23, 11:43AM CST
RPTP: 9.05 (-0.40), RGDO: 1.17 (+0.02)
Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 2:20PM CST
Merrimack (MACK) announced additional analyses from the phase III NAPOLI-1 study on MM-398 .
MACK: 10.22 (+0.40), BAX: 70.39 (+0.31), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02)
Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 2:10PM CST
Celgene (CELG) inked a deal with Zymeworks for the research, development and commercialization of bi-specific antibody therapeutics.
MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Biotech Weekly: The Failed Biotech Life Cycle And The Regado-Tobira Merger
Daniel Ward - at Seeking Alpha - Tue Jan 20, 7:00AM CST
RGDO: 1.17 (+0.02)
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), PSTI: 2.91 (+0.01), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), EGRX: 20.98 (+1.45), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
CorMedix (CRMD) Looks Good: Stock Moves 9.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:25AM CST
CorMedix (CRMD) was a big mover last session, with shares rising over 9% on the day.
CRMD: 3.27 (+0.02), RGDO: 1.17 (+0.02)
Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 4:25PM CST
Celldex Therapeutics (CLDX) and Bristol-Myers Squibb Company (BMY) announced the commencement of a phase I/II dose escalation and cohort expansion study to evaluate Celldex's varlilumab in combination with Bristol-Myers' Opdivo in patients with advanced refractory solid tumor.
CLDX: 20.97 (+0.53), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:54PM CST
Intercept Pharmaceuticals, Inc.'s (ICPT) obeticholic acid (OCA) received Breakthrough Therapy designation from the FDA for nonalcoholic steatohepatitis (NASH).
MNK: 115.01 (+2.51), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
SurModics Beats on Q1 Earnings, Reaffirms 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 9:20AM CST
SurModics, Inc.'s first-quarter fiscal 2015 (ended Dec 31, 2014) adjusted earnings of 25 cents per share beat the Zacks Consensus Estimate by 4 cents.
SRDX: 23.53 (+0.10), AMAG: 41.49 (+0.23), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:20PM CST
Alexion Pharmaceuticals' (ALXN) fourth-quarter 2014 earnings (including stock-based compensation expense) of $1.15 per share.
ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Salix Financial Results Need Correcting: Audit Committee - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:19PM CST
The audit committee of the board of directors of Salix Pharmaceuticals (SLXP) announced that the company's consolidated financials require corrections.
ALXN: 182.29 (+6.02), SLXP: 152.35 (+3.17), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:07PM CST
BioDelivery (BDSI) entered into an agreement with Meda to obtain marketing authorizations for Onsolis.
BDSI: 14.92 (+0.93), OPHT: 51.11 (+0.12), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Celgene Q4 Earnings & Revenues In Line, Revlimid Sales Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 9:51AM CST
Celgene Corporation (CELG) reported fourth-quarter 2014 earnings of 88 cents per share.
ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
MediciNova (MNOV) in Focus: Stock Moves 9.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 8:25AM CST
MediciNova (MNOV) was a big mover last session, as the company saw its shares rising roughly 10% on the day.
MNOV: 3.62 (-0.56), RGDO: 1.17 (+0.02)
Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 5:25PM CST
Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB (also known as Sanfilippo B syndrome).
BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Illumina Tops Q4 Earnings on Solid Revenues, Margin Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:30AM CST
Illumina's (ILMN) full year 2014 adjusted earnings came in at $2.74 per share, beating the Zacks Consensus Estimate by 3.4% and reflecting an improvement of 52.2% from the year-ago quarter's equivalent figure.
OPHT: 51.11 (+0.12), ILMN: 198.54 (+1.81), PRTA: 22.89 (+0.13), RGDO: 1.17 (+0.02)
Strength Seen in ZIOPHARM (ZIOP): Stock Rises 11.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:25AM CST
ZIOPHARM (ZIOP) was a big mover last session, with its shares rising roughly 12% on the day.
ZIOP: 9.64 (-0.35), RGDO: 1.17 (+0.02)
Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 5:55PM CST
Gilead Sciences, Inc. (GILD) expanded HCV licensing agreements with India-based partners to include an investigational pan-genotypic agent, GS-5816.
GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 5:30PM CST
The Medicines Company (MDCO) announced that the CHMP has issued positive opinions regarding the marketing authorization for Orbactiv, Raplixa and Kengrexal.
MDCO: 29.79 (+0.91), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Atrial Fibrillation Therapeutic Pipeline Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 3:31PM CST
The report "Atrial Fibrillation - Pipeline Review, H2 2015" provides comprehensive information on the therapeutic development for atrial fibrillation. Atrial fibrillation is the most ordinary type of arrhythmia. Atrial fibrillation is an unbalanced heartbeat that increases the threat of stroke and heart disease. Generally, the risk of developing atrial fibrillation increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The complete report is available at http://www.rnrmarketresearch.com/atrial-fibri...eport.html .
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
The 2015 Calendar Of NASH Trial Catalysts: Takeda And Tobira
Clinically Sound Investor - at Seeking Alpha - Fri Jan 23, 11:43AM CST
RPTP: 9.05 (-0.40), RGDO: 1.17 (+0.02)
Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 2:20PM CST
Merrimack (MACK) announced additional analyses from the phase III NAPOLI-1 study on MM-398 .
MACK: 10.22 (+0.40), BAX: 70.39 (+0.31), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02)
Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 2:10PM CST
Celgene (CELG) inked a deal with Zymeworks for the research, development and commercialization of bi-specific antibody therapeutics.
MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Biotech Weekly: The Failed Biotech Life Cycle And The Regado-Tobira Merger
Daniel Ward - at Seeking Alpha - Tue Jan 20, 7:00AM CST
RGDO: 1.17 (+0.02)
